MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

    • World–renowned research institutions and universities
    • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
    • Fastest growing region for healthcare companies in the U.S.
    • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

Emergent BioSolutions to buy GSK’s anthrax treatment raxibacumab

July 25, 2017

Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.

Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.

NEA makes history with $3.3B fund

July 24, 2017

New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.

GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 23, 2017

ROCKVILLE, Md.–(BUSINESS WIRE)– GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.

Granules India to Add 102 Jobs, Invest $35 Million in Fairfax County Pharmaceutical R&D, Manufacturing Operation

July 22, 2017

FAIRFAX COUNTY, Va.–(BUSINESS WIRE)–Governor Terry McAuliffe today announced that Granules India Ltd., a vertically integrated pharmaceutical company, will invest $35 million into its wholly owned subsidiary, Granules Pharmaceuticals Inc., to…

Board of Visitors Approves Academic Affiliation with Inova

July 21, 2017

The University of Virginia’s Board of Visitors on Friday approved an academic affiliation with the Inova Health System Foundation that includes a research institute and a UVA School of Medicine regional campus.

Cybersecurity, blockchain, autonomous research take spotlight in new Virginia technology funding

June 13, 2017

The governor’s office announces new awards dedicated to bolstering technology research and commercialization around several emerging markets.